This January, witness change in action at the 2022 NF Congressional Briefing! Hear from NF leaders, researchers, and an NF patient about federally funded NF research and raising NF awareness. Our team will address the CDMRP, National Institutes of Health, and other public and private research partnerships, whose work helped lead to 2020’s first-ever FDA-approved drug for neurofibromatosis type 1. Take a virtual seat and listen to the conversations that set things in motion and transform lives! Join our Senate meeting on January 6 or House of Representatives meeting on January 7. Registration link to follow in the first week of December.